MX2019005627A - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica. - Google Patents

Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.

Info

Publication number
MX2019005627A
MX2019005627A MX2019005627A MX2019005627A MX2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A
Authority
MX
Mexico
Prior art keywords
atherosclerosis
pcsk9
ldl
therapies
cardiovascular disease
Prior art date
Application number
MX2019005627A
Other languages
English (en)
Inventor
Wasserman Scott
Andrew Donald Scott Robert
Mudalinayake Somaratne Ransi
Honarpour Narimon
Nicholls Stephen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019005627A publication Critical patent/MX2019005627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se proporcionan combinaciones de terapias que posibilitan el tratamiento, incluyendo la regresion, de la ateroesclerosis y/o la mejora de los resultados cardiovasculares. Descrito de modo general, esto incluye un primer agente reductor del LDL-C distinto de PCSK9 (tal como una estatina u otra terapia reductora de LDL-C distinta de PCSK9), combinado con una segunda terapia con inhibidor de PCSK9 (tal como un anticuerpo contra PCSK9 o anti-ARN). Se ha determinado que la aplicacion de ambas terapias, a niveles adecuadamente elevadas a fin de reducir el nivel de LDL-C del sujeto hasta niveles muy bajos, durante un periodo de tiempo adecuado, proporciona un beneficio anadido de proteccion adicional frente a la ateroesclerosis y mejora los resultados cardiovasculares de un sujeto.
MX2019005627A 2016-11-14 2017-11-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica. MX2019005627A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10
PCT/US2017/061346 WO2018089912A2 (en) 2016-11-14 2017-11-13 Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease

Publications (1)

Publication Number Publication Date
MX2019005627A true MX2019005627A (es) 2019-10-14

Family

ID=60484496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005627A MX2019005627A (es) 2016-11-14 2017-11-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.

Country Status (17)

Country Link
US (1) US20200368350A1 (es)
EP (1) EP3538149A2 (es)
JP (2) JP2019533715A (es)
KR (1) KR20190085963A (es)
CN (1) CN110234350A (es)
AU (1) AU2017356219A1 (es)
BR (1) BR112019009726A2 (es)
CA (1) CA3043700A1 (es)
CL (2) CL2019001304A1 (es)
CO (1) CO2019004814A2 (es)
IL (1) IL266579A (es)
JO (1) JOP20190112A1 (es)
MA (1) MA46758A (es)
MX (1) MX2019005627A (es)
TN (1) TN2019000156A1 (es)
WO (1) WO2018089912A2 (es)
ZA (1) ZA201902975B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
AU2019315823A1 (en) * 2018-07-31 2021-04-01 Wen Tan New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
CN114127770A (zh) * 2019-07-19 2022-03-01 电子湾有限公司 样本增量监视
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3249052B1 (en) 2006-05-11 2019-04-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
BRPI1010689A2 (pt) 2009-06-15 2016-03-15 Alnylam Pharmaceuticals Inc "dsrna formulado por lipídios direcionados para o gene pcsk9"
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
MA34818B1 (fr) 2010-12-22 2014-01-02 Genentech Inc Anticorps anti-pcsk9 et procédés d'utilisation
CN103562227B (zh) 2011-02-11 2016-12-21 诺瓦提斯公司 Pcsk9拮抗剂
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk
EP3650852B1 (en) * 2015-01-09 2021-08-18 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease

Also Published As

Publication number Publication date
WO2018089912A2 (en) 2018-05-17
MA46758A (fr) 2019-09-18
JOP20190112A1 (ar) 2019-05-14
CL2020002993A1 (es) 2021-05-14
KR20190085963A (ko) 2019-07-19
JP2023071715A (ja) 2023-05-23
JP2019533715A (ja) 2019-11-21
BR112019009726A2 (pt) 2019-08-13
TN2019000156A1 (en) 2020-10-05
CO2019004814A2 (es) 2019-07-31
CN110234350A (zh) 2019-09-13
WO2018089912A3 (en) 2018-06-21
CA3043700A1 (en) 2018-05-17
ZA201902975B (en) 2020-01-29
CL2019001304A1 (es) 2019-09-23
IL266579A (en) 2019-07-31
US20200368350A1 (en) 2020-11-26
EP3538149A2 (en) 2019-09-18
AU2017356219A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
TN2019000156A1 (en) Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2018013591A (es) Terapias combinadas de inhibidores hdac e inhibidores de pd-1.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2021010875A (es) Composiciones de éster de ácido cannabinoide y sus usos.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
PH12017500461A1 (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
WO2018052891A3 (en) MODULATION OF PCSK9 AND LDLR BY INHIBITION OF DRP1
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
GB2549031A (en) Methods and drug therapies for patency of occluded blood vessels following angioplasty
WO2018049003A8 (en) ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND THEIR METHODS OF USE
MX2021001394A (es) Metodo para mejorar la eficacia de un agente anticanceroso.
MY166357A (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
EA201991160A1 (ru) Средства комбинированной терапии атеросклероза, включая атеросклеротическое сердечно-сосудистое заболевание
WO2019039937A8 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER